SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the “Trial”) of ruxolitinib cream (the “Product”) in patients with mild to moderate atopic dermatitis (AD)…
Read More
Recent posts
- China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
- Evergreen Profits Invests in Academic Labs Following $AAX Listing on Biconomy, Advancing a Universal Knowledge Layer for Decentralized AI Learning
- Daycare AccountingPRO Unveils Innovative Financial Solutions for Childcare Businesses
- XRP Positioned for Tenfold Growth as Institutional Funds Accelerate
- Safeguarding Industry and Commerce: Anern ESS Stackable Lithium Batteries Provide Worry-Free Power Guarantee
